PharmaShots | Incisive News in 3 Shots

Subscribe Now

MSI-H

Merck Reports the US FDA's Acceptance of Keytruda's sBLA for Review to Treat MSI-H/dMMR Advanced Endometrial Carcinoma

Merck Reports the US FDA's Acceptance of Keytruda's sBLA for Review to Treat MSI-H/dMMR Advanced Endometrial Carcinoma

August 11, 2021

Merck and Eisai's Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive the US FDA's Approval for the Treatment of Advanced Endometrial Carcinoma

Merck and Eisai's Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive the US FDA's Approval for the Treatment of Advanced Endo...

July 22, 2021

BeiGene Reports NMPA's Acceptance of sBLA for Tislelizumab to Treat MSI-H or dMMR Solid Tumors

BeiGene Reports NMPA's Acceptance of sBLA for Tislelizumab to Treat MSI-H or dMMR Solid Tumors

June 8, 2021

Merck's Keytruda (pembrolizumab) Receives EC's Approval as 1L Treatment for Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer

Merck's Keytruda (pembrolizumab) Receives EC's Approval as 1L Treatment for Metastatic Microsatellite Instability-High (MSI-H) or...

January 27, 2021

Merck's Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 for Patients with MSI-H Colorectal Cancer #ASCO20

Merck's Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 for Patients with MSI-H Colorectal Cancer #ASCO20

June 1, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us